RGNX REGENXBIO Inc.

NASDAQ
$7.38

REGENXBIO Inc. (RGNX) is confirmed to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $1.13 per share.

REGENXBIO Beat Consensus Estimates
Thursday, November 5, 2026 · 7:05 AM ET
Earnings Date
4th Quarter, Dec 2026
Nov 5
Thursday · 7:05 AM ET
Earnings Whisper
-
vs ($1.13)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.34

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.